See more : Dalrada Financial Corporation (DFCO) Income Statement Analysis – Financial Results
Complete financial analysis of Recce Pharmaceuticals Ltd (RCE.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Recce Pharmaceuticals Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- ETS Holdings Co.,Ltd. (1789.T) Income Statement Analysis – Financial Results
- Hochschild Mining plc (HOC.L) Income Statement Analysis – Financial Results
- AMFI Corp. (AFIPA) Income Statement Analysis – Financial Results
- American Power Group Corporation (APGI) Income Statement Analysis – Financial Results
- Fosterville South Exploration Ltd. (FSX.V) Income Statement Analysis – Financial Results
Recce Pharmaceuticals Ltd (RCE.AX)
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 4.37M | 3.08M | 1.64M | 1.12M | 679.62K | 1.29M | 139.30K | 177.02K | 113.85K | 97.14K | 387.00 |
| Cost of Revenue | 366.77K | 217.16K | 187.67K | 295.63K | 200.82K | 56.09K | 53.12K | 25.51K | 16.66K | 111.12K | 61.01K | 33.55K |
| Gross Profit | -366.77K | 4.15M | 2.90M | 1.34M | 920.91K | 623.54K | 1.24M | 113.78K | 160.36K | 2.73K | 36.13K | -33.17K |
| Gross Profit Ratio | 0.00% | 95.03% | 93.92% | 81.94% | 82.10% | 91.75% | 95.88% | 81.68% | 90.59% | 2.40% | 37.19% | -8,570.03% |
| Research & Development | 0.00 | 7.17M | 6.22M | 5.56M | 1.99M | 416.35K | 372.17K | 999.36K | 142.25K | 53.88K | 8.66K | 8.82K |
| General & Administrative | 0.00 | 4.11M | 2.37M | 6.81M | 1.59M | 1.60M | 1.34M | 1.54M | 4.19M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 1.12M | 994.27K | 695.51K | 190.36K | 1.77M | 1.53M | 1.62M | 617.31K | 0.00 | 0.00 | 0.00 |
| SG&A | 21.68M | 17.11M | 13.96M | 15.07M | 5.21M | 3.36M | 2.87M | 3.16M | 4.80M | 409.50K | 227.15K | 201.53K |
| Other Expenses | 0.00 | 4.28M | 1.53M | 1.59M | 974.23K | 571.34K | 1.19M | 110.88K | -197.97K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.68M | 17.11M | 13.96M | 15.07M | 5.21M | 3.36M | 2.87M | 3.16M | 4.80M | 452.65K | 308.32K | 259.16K |
| Cost & Expenses | 22.05M | 17.33M | 14.15M | 15.36M | 5.41M | 3.42M | 2.92M | 3.18M | 4.82M | 563.77K | 369.33K | 292.71K |
| Interest Income | 187.00K | 66.19K | 91.00K | 105.76K | 25.80K | 7.00K | 12.02K | 50.63K | 44.10K | 251.00 | 228.00 | 134.00 |
| Interest Expense | 846.85K | 183.27K | 11.93K | 12.14K | 56.44K | 56.69K | 54.31K | 2.41K | 9.04K | 0.00 | 228.00 | 134.00 |
| Depreciation & Amortization | 366.77K | 217.16K | 187.67K | 295.63K | 200.82K | 56.09K | 53.12K | 25.51K | 16.66K | 9.51K | 8.36K | 5.78K |
| EBITDA | -21.35M | -16.99M | -10.80M | -14.77M | -5.13M | -2.68M | -2.86M | -3.16M | -4.95M | -439.62K | -263.83K | -286.55K |
| EBITDA Ratio | 0.00% | -391.93% | -452.60% | -920.30% | -464.19% | -494.84% | -222.53% | -2,267.91% | -2,714.19% | -386.82% | -271.59% | -74,044.19% |
| Operating Income | -22.05M | -17.33M | -14.15M | -15.36M | -5.41M | -3.42M | -2.92M | -3.18M | -4.82M | -449.92K | -272.19K | -292.33K |
| Operating Income Ratio | 0.00% | -396.90% | -458.69% | -938.36% | -482.10% | -503.09% | -226.66% | -2,286.23% | -2,723.60% | -395.17% | -280.20% | -75,536.43% |
| Total Other Income/Expenses | -516.48K | 4.25M | -4.42M | -1.57M | -1.10M | -49.70K | 1.25M | -119.49K | -328.97K | -251.00 | -228.00 | -134.00 |
| Income Before Tax | -22.57M | -17.39M | -14.07M | -15.08M | -5.39M | -3.47M | -2.96M | -3.16M | -4.97M | -450.17K | -272.42K | -292.46K |
| Income Before Tax Ratio | 0.00% | -398.35% | -456.12% | -920.95% | -480.37% | -510.40% | -229.94% | -2,272.01% | -2,809.44% | -395.39% | -280.43% | -75,571.06% |
| Income Tax Expense | -4.91M | -4.31M | -3.08M | -1.57M | -1.07M | -679.62K | -1.29M | -139.30K | -132.92K | 0.00 | 0.00 | 0.00 |
| Net Income | -17.66M | -13.08M | -10.99M | -13.51M | -4.32M | -2.79M | -1.67M | -3.03M | -4.84M | -450.17K | -272.42K | -292.46K |
| Net Income Ratio | 0.00% | -299.58% | -356.12% | -825.30% | -384.83% | -410.40% | -129.94% | -2,172.01% | -2,734.36% | -395.39% | -280.43% | -75,571.06% |
| EPS | -0.10 | -0.07 | -0.06 | -0.09 | -0.03 | -0.03 | -0.02 | -0.04 | -0.09 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | -0.10 | -0.07 | -0.06 | -0.09 | -0.03 | -0.03 | -0.02 | -0.04 | -0.09 | -0.01 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 177.10M | 175.71M | 175.87M | 156.95M | 128.48M | 95.42M | 85.57M | 77.38M | 56.79M | 33.31M | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 177.10M | 175.71M | 175.87M | 156.95M | 128.48M | 95.42M | 85.57M | 77.38M | 56.79M | 34.12M | 0.00 | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports